Amed Ouattara

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8121590/publications.pdf

Version: 2024-02-01

43 papers	2,029 citations	304743 22 h-index	254184 43 g-index
47 all docs	47 docs citations	47 times ranked	2318 citing authors

#	Article	IF	Citations
1	Differential Incidence of Malaria in Neighboring Villages in a High-Transmission Setting of Southern Mali. American Journal of Tropical Medicine and Hygiene, 2022, 106, 1209-1214.	1.4	2
2	An In Silico Analysis of Malaria Pre-Erythrocytic-Stage Antigens Interpreting Worldwide Genetic Data to Suggest Vaccine Candidate Variants and Epitopes. Microorganisms, 2022, 10, 1090.	3.6	2
3	#63: Antibodies to Peptides Representing Plasmodium falciparum Circumsporozoite Protein Reflect Acquisition of Naturally Acquired Immunity in Malian Adults and Children. Journal of the Pediatric Infectious Diseases Society, 2021, 10, S10-S12.	1.3	0
4	Whole-genome analysis of Malawian Plasmodium falciparum isolates identifies possible targets of allele-specific immunity to clinical malaria. PLoS Genetics, 2021, 17, e1009576.	3.5	4
5	Immunoprofiles associated with controlled human malaria infection and naturally acquired immunity identify a shared IgA pre-erythrocytic immunoproteome. Npj Vaccines, 2021, 6, 115.	6.0	2
6	Epitope-Specific Antibody Responses to a Plasmodium falciparum Subunit Vaccine Target in a Malaria-Endemic Population. Journal of Infectious Diseases, 2021, 223, 1943-1947.	4.0	3
7	Successful Profiling of Plasmodium falciparum var Gene Expression in Clinical Samples via a Custom Capture Array. MSystems, 2021, 6, e0022621.	3.8	4
8	Strains used in whole organism Plasmodium falciparum vaccine trials differ in genome structure, sequence, and immunogenic potential. Genome Medicine, 2020, 12, 6.	8.2	61
9	Epitope-based sieve analysis of Plasmodium falciparum sequences from a FMP2.1/AS02A vaccine trial is consistent with differential vaccine efficacy against immunologically relevant AMA1 variants. Vaccine, 2020, 38, 5700-5706.	3.8	5
10	Microarray analyses reveal strain-specific antibody responses to Plasmodium falciparum apical membrane antigen 1 variants following natural infection and vaccination. Scientific Reports, 2020, 10, 3952.	3.3	24
11	Genetic diversity and drug resistance surveillance of Plasmodium falciparum for malaria elimination: is there an ideal tool for resource-limited sub-Saharan Africa?. Malaria Journal, 2019, 18, 217.	2.3	46
12	Serologic responses to the PfEMP1 DBL-CIDR head structure may be a better indicator of malaria exposure than those to the DBL-Î± tag. Malaria Journal, 2019, 18, 273.	2.3	6
13	Immunoglobulin G subclass and antibody avidity responses in Malian children immunized with Plasmodium falciparum apical membrane antigen 1 vaccine candidate FMP2.1/AS02A. Malaria Journal, 2019, 18, 13.	2.3	8
14	Antibodies to Peptides in Semiconserved Domains of RIFINs and STEVORs Correlate with Malaria Exposure. MSphere, 2019, 4, .	2.9	23
15	Children with cerebral malaria or severe malarial anaemia lack immunity to distinct variant surface antigen subsets. Scientific Reports, 2018, 8, 6281.	3.3	31
16	Prevalence of molecular markers of sulfadoxineâ€“pyrimethamine and artemisinin resistance in Plasmodium falciparum from Pakistan. Malaria Journal, 2018, 17, 471.	2.3	17
17	Extent and Dynamics of Polymorphism in the Malaria Vaccine Candidate Plasmodium falciparum Reticulocyteâ€“Binding Protein Homologue-5 in Kalifabougou, Mali. American Journal of Tropical Medicine and Hygiene, 2018, 99, 43-50.	1.4	10
18	Mother-Newborn Pairs in Malawi Have Similar Antibody Repertoires to Diverse Malaria Antigens. Vaccine Journal, 2017, 24, .	3.1	3

#	Article	IF	Citations
19	Reduced ex vivo susceptibility of Plasmodium falciparum after oral artemetherâ€“lumefantrine treatment in Mali. Malaria Journal, 2017, 16, 59.	2.3	27
20	A novel method for extracting nucleic acids from dried blood spots for ultrasensitive detection of low-densityÂPlasmodium falciparum and Plasmodium vivaxÂinfections. Malaria Journal, 2017, 16, 377.	2.3	56
21	Plasmodium vivax Infections over 3 Years in Duffy Blood Group Negative Malians in Bandiagara, Mali. American Journal of Tropical Medicine and Hygiene, 2017, 97, 744-752.	1.4	52
22	Seroreactivity to a Large Panel of Field-Derived Plasmodium falciparum Apical Membrane Antigen 1 and Merozoite Surface Protein 1 Variants Reflects Seasonal and Lifetime Acquired Responses to Malaria. American Journal of Tropical Medicine and Hygiene, 2015, 92, 9-12.	1.4	20
23	Polymorphisms in the K13-Propeller Gene in Artemisinin-Susceptible Plasmodium falciparum Parasites from Bougoula-Hameau and Bandiagara, Mali. American Journal of Tropical Medicine and Hygiene, 2015, 92, 1202-1206.	1.4	89
24	Differential Recognition of Terminal Extracellular Plasmodium falciparum VAR2CSA Domains by Sera from Multigravid, Malaria-Exposed Malian Women. American Journal of Tropical Medicine and Hygiene, 2015, 92, 1190-1194.	1.4	11
25	Designing malaria vaccines to circumvent antigen variability. Vaccine, 2015, 33, 7506-7512.	3.8	54
26	Vaccines Against Malaria. Clinical Infectious Diseases, 2015, 60, 930-936.	5.8	62
27	Variation in the Circumsporozoite Protein of Plasmodium falciparum: Vaccine Development Implications. PLoS ONE, 2014, 9, e101783.	2.5	22
28	Molecular Basis of Allele-Specific Efficacy of a Blood-Stage Malaria Vaccine: Vaccine Development Implications. Journal of Infectious Diseases, 2013, 207, 511-519.	4.0	66
29	Prevalence and patterns of antifolate and chloroquine drug resistance markers in Plasmodium vivax across Pakistan. Malaria Journal, 2013, 12, 310.	2.3	24
30	Seroreactivity to Plasmodium falciparum Erythrocyte Membrane Protein 1 Intracellular Domain in Malaria-Exposed Children and Adults. Journal of Infectious Diseases, 2013, 208, 1514-1519.	4.0	20
31	Extended Safety, Immunogenicity and Efficacy of a Blood-Stage Malaria Vaccine in Malian Children: 24-Month Follow-Up of a Randomized, Double-Blinded Phase 2 Trial. PLoS ONE, 2013, 8, e79323.	2.5	38
32	False-Negative Rapid Diagnostic Tests for Malaria and Deletion of the Histidine-Rich Repeat Region of the hrp2 Gene â€. American Journal of Tropical Medicine and Hygiene, 2012, 86, 194-198.	1.4	241
33	Use of a pLDH-based dipstick in the diagnostic and therapeutic follow-up of malaria patients in Mali. Malaria Journal, 2011, 10, 345.	2.3	13
34	A Field Trial to Assess a Blood-Stage Malaria Vaccine. New England Journal of Medicine, 2011, 365, 1004-1013.	27.0	311
35	Lack of allele-specific efficacy of a bivalent AMA1 malaria vaccine. Malaria Journal, 2010, 9, 175.	2.3	61
36	Extreme Polymorphism in a Vaccine Antigen and Risk of Clinical Malaria: Implications for Vaccine Development. Science Translational Medicine, 2009, 1, 2ra5.	12.4	154

#	Article	IF	Citations
37	Population structure of the genes encoding the polymorphic Plasmodium falciparum apical membrane antigen 1: Implications for vaccine design. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 7857-7862.	7.1	83
38	Dynamics of Polymorphism in a Malaria Vaccine Antigen at a Vaccine-Testing Site in Mali. PLoS Medicine, 2007, 4, e93.	8.4	94
39	Space-time clustering of childhood malaria at the household level: a dynamic cohort in a Mali village. BMC Public Health, 2006, 6, 286.	2.9	123
40	A RANDOMIZED TRIAL OF ARTESUNATEâ€“SULFAMETHOXYPYRAZINEâ€“PYRIMETHAMINE VERSUS ARTEMETHERâ€“LUMEFANTRINE FOR THE TREATMENT OF UNCOMPLICATED PLASMODIUM FALCIPARUM MALARIA IN MALI. American Journal of Tropical Medicine and Hygiene, 2006, 75, 630-636.	1.4	32
41	A randomized trial of artesunate-sulfamethoxypyrazine-pyrimethamine versus artemether-lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in Mali. American Journal of Tropical Medicine and Hygiene, 2006, 75, 630-6.	1.4	24
42	Molecular Diagnosis of Resistance to Antimalarial Drugs during Epidemics and in War Zones. Journal of Infectious Diseases, 2004, 190, 853-855.	4.0	52
43	Evaluation of an Immunofluorescent-Antibody Test Using Monoclonal Antibodies Directed against Enterocytozoon bieneusi and Encephalitozoon intestinalis for Diagnosis of Intestinal Microsporidiosis in Bamako (Mali). Journal of Clinical Microbiology, 2002, 40, 1715-1718.	3.9	42